Purpose: L612, a human IgM monoclonal antibody produced by an EBV-transformed human
B-cell line, binds to ganglioside GM3 and kills GM3-positive human melanoma cells in the …

Purpose: A human monoclonal antibody (L612 HuMAb) that binds to ganglioside GM3 has
been developed in our laboratory. L612 HuMAb is a 100% human IgM protein. L612 HuMAb …

Ganglioside GM2, which is one of the major gangliosides expressed on the cell surface of
human tumors of neuroectodermal origin, has been focused on as a target molecule for …

In this study we report the characterization of a human monoclonal antibody (HuMab), L612,
that reacts with ganglioside GM3 and has therapeutic application for the treatment of human …

Several gangliosides such as GM2, GD2, and GD3 have been thought of as target
molecules for active or passive immunotherapy of human cancers because of their dominant …

A human B-lymphoblastoid cell clone, L55-81, that produces human monoclonal antibody
(MAb) to ganglioside GM2 was established from peripheral blood B lymphocytes of a …

PURPOSE: KM871 is a chimeric monoclonal antibody against the ganglioside antigen GD3,
which is highly expressed on melanoma cells. We conducted an open-label, dose …

Ganglioside GD3, which is one of the major gangliosides expressed on the cell surface of
human tumors of neuroectodermal origin has been focused on as a target molecule for …

GD3 is a major ganglioside of human melanoma and was shown to be an effective target for
passive immunotherapy with murine monoclonal antibodies. It was noted earlier that GD3 …

Gangliosides expressed in malignant melanoma are potential targets for immunotherapy.
Immunization of melanoma patients with vaccines containing purified GM2 ganglioside has …